Sanofi-aventis announced that the GetGoal-X Phase 3 study of lixisenatide, a once-daily GLP-1 receptor agonist, has achieved primary efficacy endpoint.
Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus.
The US Department of Agriculture announced the release of the 2010 Dietary Guidelines for Americans, the federal government's evidence-based nutritional guidance to promote health, reduce the risk of chronic diseases, and reduce the prevalence of overweight and obesity through improved nutrition and physical activity....
As I head to the lab for a blood test this morning for my endo appointment next week, I’m reminded of how I used to approach my three month blood test.…
New research, funded by Diabetes UK, has found that use of an artificial pancreas by woman suffering from type 1 diabetes during pregnancy may drastically reduce cases of stillbirth and mortality rates...